

NERVIANO MEDICAL SCIENCES

Nerviano Medical Sciences announces participation at WCLC 2026 with a poster presentation

Milan, Italy, 7 September 2026 – Nerviano Medical Sciences S.r.l. (“NMS”), a global oncology-focused biopharmaceutical company, today announces its participation in the upcoming World Conference on Lung Cancer (“WCLC”) of the International Association for the Study of Lung Cancer (“IASLC”), taking place in Seoul, Republic of Korea, from September 12 to 15, 2026.

At the meeting, NMS will present a scientific poster featuring its proprietary PARP7 inhibitor, atamparib.

Title: “A Phase Ib/II Study of Atamparib, a PARP7 Inhibitor, in Patients with Advanced Solid Tumors”

Presenter: Dr. Xinru Chen, Shanghai East Hospital

Poster Section: Clinical Trials in Progress

Poster Board Number: P2-372

Abstract Control Number: 606

Date & Time: Monday, September 14, 2026 at 10:30 AM KST / UTC +9

Link to full poster abstract: <https://cattendee.abstractsonline.com/meeting/21487/Session/217>

This ongoing phase 1b/2 trial is evaluating atamparib, a potential first-in-class, orally bioavailable, selective PARP7 inhibitor. Through its unique dual mechanism of action, atamparib disrupts KRAS-driven and other oncogenic signaling pathways, while activating innate immune responses. The study is currently exploring higher dose levels and generating proof-of-concept data in selected patients with advanced or metastatic NSCLC adenocarcinoma.

We look forward to engaging with the scientific community at the IASLC 2026 WCLC and sharing insights from our work.

About Atamparib

Atamparib was acquired by NMS from Ribon Therapeutics in November 2024 (previously RBN 2397/ONO 7119). It has demonstrated a favorable tolerability profile in prior Phase I/II clinical evaluation (NCT04053673, NCT05127590, JRCT2031210373). Supported by new preclinical data and early signs of clinical activity, NMS is advancing atamparib for the treatment of advanced or metastatic solid tumors, with the goal of addressing significant unmet medical needs as a single agent and in combination regimens.

About NMS

NMS is a global, integrated biopharmaceutical company focused on the discovery and development of innovative oncology therapies. With affiliates in Nerviano/Corsico (Italy), Boston (USA), and Shanghai (China),

NERVIANO MEDICAL SCIENCES

NMS leverages deep expertise in drug discovery and translational medicine to advance its pipeline of novel candidates from bench to bedside.

For more information, visit <https://www.nervianoms.com>

Media Relations: mediarelations@nervianoms.com